Muscarinic Acetylcholine Receptor - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509241479

Publication Date:

September 6, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Muscarinic Acetylcholine Receptor (m-g protein coupled Receptor) is an autoantibody in the serum of patients with myasthenia gravis.
The global market for Muscarinic Acetylcholine Receptor was estimated to be worth US$ 161 million in 2023 and is forecast to a readjusted size of US$ 270.9 million by 2030 with a CAGR of 4.5% during the forecast period 2024-2030
Research and drug development related to muscarinic acetylcholine receptors are ongoing, with potential applications in the treatment of conditions like asthma, chronic obstructive pulmonary disease (COPD), and neurological disorders.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Muscarinic Acetylcholine Receptor, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Muscarinic Acetylcholine Receptor by region & country, by Type, and by Application.
The Muscarinic Acetylcholine Receptor market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Muscarinic Acetylcholine Receptor.
麻豆原创 Segmentation
By Company
Anavex Life Sciences Corp
AstraZeneca Plc
Heptares Therapeutics Ltd
Karuna Pharmaceuticals Inc
NeuroHealing Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Segment by Type:
M1
M4
M5
Others
Segment by Application
Attention Deficit Hyperactivity Disorder
Psychiatric Disorders
Alzheimer's Disease
Chronic Obstructive Pulmonary Disease
Memory Impairment
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Muscarinic Acetylcholine Receptor manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Muscarinic Acetylcholine Receptor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Muscarinic Acetylcholine Receptor in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Muscarinic Acetylcholine Receptor Product Introduction
1.2 Global Muscarinic Acetylcholine Receptor 麻豆原创 Size Forecast
1.3 Muscarinic Acetylcholine Receptor 麻豆原创 Trends & Drivers
1.3.1 Muscarinic Acetylcholine Receptor Industry Trends
1.3.2 Muscarinic Acetylcholine Receptor 麻豆原创 Drivers & Opportunity
1.3.3 Muscarinic Acetylcholine Receptor 麻豆原创 Challenges
1.3.4 Muscarinic Acetylcholine Receptor 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Muscarinic Acetylcholine Receptor Players Revenue Ranking (2023)
2.2 Global Muscarinic Acetylcholine Receptor Revenue by Company (2019-2024)
2.3 Key Companies Muscarinic Acetylcholine Receptor Manufacturing Base Distribution and Headquarters
2.4 Key Companies Muscarinic Acetylcholine Receptor Product Offered
2.5 Key Companies Time to Begin Mass Production of Muscarinic Acetylcholine Receptor
2.6 Muscarinic Acetylcholine Receptor 麻豆原创 Competitive Analysis
2.6.1 Muscarinic Acetylcholine Receptor 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Muscarinic Acetylcholine Receptor Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Muscarinic Acetylcholine Receptor as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 M1
3.1.2 M4
3.1.3 M5
3.1.4 Others
3.2 Global Muscarinic Acetylcholine Receptor Sales Value by Type
3.2.1 Global Muscarinic Acetylcholine Receptor Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Muscarinic Acetylcholine Receptor Sales Value, by Type (2019-2030)
3.2.3 Global Muscarinic Acetylcholine Receptor Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Attention Deficit Hyperactivity Disorder
4.1.2 Psychiatric Disorders
4.1.3 Alzheimer's Disease
4.1.4 Chronic Obstructive Pulmonary Disease
4.1.5 Memory Impairment
4.2 Global Muscarinic Acetylcholine Receptor Sales Value by Application
4.2.1 Global Muscarinic Acetylcholine Receptor Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Muscarinic Acetylcholine Receptor Sales Value, by Application (2019-2030)
4.2.3 Global Muscarinic Acetylcholine Receptor Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Muscarinic Acetylcholine Receptor Sales Value by Region
5.1.1 Global Muscarinic Acetylcholine Receptor Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Muscarinic Acetylcholine Receptor Sales Value by Region (2019-2024)
5.1.3 Global Muscarinic Acetylcholine Receptor Sales Value by Region (2025-2030)
5.1.4 Global Muscarinic Acetylcholine Receptor Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Muscarinic Acetylcholine Receptor Sales Value, 2019-2030
5.2.2 North America Muscarinic Acetylcholine Receptor Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Muscarinic Acetylcholine Receptor Sales Value, 2019-2030
5.3.2 Europe Muscarinic Acetylcholine Receptor Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Muscarinic Acetylcholine Receptor Sales Value, 2019-2030
5.4.2 Asia Pacific Muscarinic Acetylcholine Receptor Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Muscarinic Acetylcholine Receptor Sales Value, 2019-2030
5.5.2 South America Muscarinic Acetylcholine Receptor Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Muscarinic Acetylcholine Receptor Sales Value, 2019-2030
5.6.2 Middle East & Africa Muscarinic Acetylcholine Receptor Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Muscarinic Acetylcholine Receptor Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Muscarinic Acetylcholine Receptor Sales Value
6.3 United States
6.3.1 United States Muscarinic Acetylcholine Receptor Sales Value, 2019-2030
6.3.2 United States Muscarinic Acetylcholine Receptor Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Muscarinic Acetylcholine Receptor Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Muscarinic Acetylcholine Receptor Sales Value, 2019-2030
6.4.2 Europe Muscarinic Acetylcholine Receptor Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Muscarinic Acetylcholine Receptor Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Muscarinic Acetylcholine Receptor Sales Value, 2019-2030
6.5.2 China Muscarinic Acetylcholine Receptor Sales Value by Type (%), 2023 VS 2030
6.5.3 China Muscarinic Acetylcholine Receptor Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Muscarinic Acetylcholine Receptor Sales Value, 2019-2030
6.6.2 Japan Muscarinic Acetylcholine Receptor Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Muscarinic Acetylcholine Receptor Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Muscarinic Acetylcholine Receptor Sales Value, 2019-2030
6.7.2 South Korea Muscarinic Acetylcholine Receptor Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Muscarinic Acetylcholine Receptor Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Muscarinic Acetylcholine Receptor Sales Value, 2019-2030
6.8.2 Southeast Asia Muscarinic Acetylcholine Receptor Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Muscarinic Acetylcholine Receptor Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Muscarinic Acetylcholine Receptor Sales Value, 2019-2030
6.9.2 India Muscarinic Acetylcholine Receptor Sales Value by Type (%), 2023 VS 2030
6.9.3 India Muscarinic Acetylcholine Receptor Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Anavex Life Sciences Corp
7.1.1 Anavex Life Sciences Corp Profile
7.1.2 Anavex Life Sciences Corp Main Business
7.1.3 Anavex Life Sciences Corp Muscarinic Acetylcholine Receptor Products, Services and Solutions
7.1.4 Anavex Life Sciences Corp Muscarinic Acetylcholine Receptor Revenue (US$ Million) & (2019-2024)
7.1.5 Anavex Life Sciences Corp Recent Developments
7.2 AstraZeneca Plc
7.2.1 AstraZeneca Plc Profile
7.2.2 AstraZeneca Plc Main Business
7.2.3 AstraZeneca Plc Muscarinic Acetylcholine Receptor Products, Services and Solutions
7.2.4 AstraZeneca Plc Muscarinic Acetylcholine Receptor Revenue (US$ Million) & (2019-2024)
7.2.5 AstraZeneca Plc Recent Developments
7.3 Heptares Therapeutics Ltd
7.3.1 Heptares Therapeutics Ltd Profile
7.3.2 Heptares Therapeutics Ltd Main Business
7.3.3 Heptares Therapeutics Ltd Muscarinic Acetylcholine Receptor Products, Services and Solutions
7.3.4 Heptares Therapeutics Ltd Muscarinic Acetylcholine Receptor Revenue (US$ Million) & (2019-2024)
7.3.5 Karuna Pharmaceuticals Inc Recent Developments
7.4 Karuna Pharmaceuticals Inc
7.4.1 Karuna Pharmaceuticals Inc Profile
7.4.2 Karuna Pharmaceuticals Inc Main Business
7.4.3 Karuna Pharmaceuticals Inc Muscarinic Acetylcholine Receptor Products, Services and Solutions
7.4.4 Karuna Pharmaceuticals Inc Muscarinic Acetylcholine Receptor Revenue (US$ Million) & (2019-2024)
7.4.5 Karuna Pharmaceuticals Inc Recent Developments
7.5 NeuroHealing Pharmaceuticals Inc
7.5.1 NeuroHealing Pharmaceuticals Inc Profile
7.5.2 NeuroHealing Pharmaceuticals Inc Main Business
7.5.3 NeuroHealing Pharmaceuticals Inc Muscarinic Acetylcholine Receptor Products, Services and Solutions
7.5.4 NeuroHealing Pharmaceuticals Inc Muscarinic Acetylcholine Receptor Revenue (US$ Million) & (2019-2024)
7.5.5 NeuroHealing Pharmaceuticals Inc Recent Developments
7.6 Sumitomo Dainippon Pharma Co Ltd
7.6.1 Sumitomo Dainippon Pharma Co Ltd Profile
7.6.2 Sumitomo Dainippon Pharma Co Ltd Main Business
7.6.3 Sumitomo Dainippon Pharma Co Ltd Muscarinic Acetylcholine Receptor Products, Services and Solutions
7.6.4 Sumitomo Dainippon Pharma Co Ltd Muscarinic Acetylcholine Receptor Revenue (US$ Million) & (2019-2024)
7.6.5 Sumitomo Dainippon Pharma Co Ltd Recent Developments
8 Industry Chain Analysis
8.1 Muscarinic Acetylcholine Receptor Industrial Chain
8.2 Muscarinic Acetylcholine Receptor Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Muscarinic Acetylcholine Receptor Sales Model
8.5.2 Sales Channel
8.5.3 Muscarinic Acetylcholine Receptor Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Anavex Life Sciences Corp
AstraZeneca Plc
Heptares Therapeutics Ltd
Karuna Pharmaceuticals Inc
NeuroHealing Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.